MPC 9055
Alternative Names: MPC-9055; ViveconLatest Information Update: 01 Sep 2010
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class Antiretrovirals; Small molecules
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - HIV infections
Highest Development Phases
- Suspended HIV-1 infections
Most Recent Events
- 11 Feb 2009 Pharmacodynamics data from an in vitro study in HIV-1 infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
- 11 Feb 2009 Adverse events & pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
- 31 Jan 2008 Phase-I clinical trials in HIV-1 infections treatment in USA (PO)